Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ikena Oncology ERK5 inhibitor
- Development stage
- Discontinued
- Lead developer
- ImageneBio
- Modality
- Small Molecules
01
Overview
Ikena Oncology's ERK5 inhibitor is a preclinical small molecule program designed to target the ERK5 kinase (also known as MAPK7) within the RAS signaling pathway. It was specifically developed to treat RAS-pathway driven tumors, including KRAS-mutant pancreatic cancer and lung adenocarcinoma. Preclinical studies demonstrated that the inhibitor possesses single-agent activity and exhibits synergistic anti-tumor effects when combined with MEK inhibition. Following Ikena Oncology's merger with Inmagene Biopharmaceuticals in July 2025 to form ImageneBio, the company shifted its strategic focus toward inflammatory and autoimmune diseases, effectively deprioritizing and discontinuing its oncology pipeline, including the ERK5 program.
- Other names
- ERK5 inhibitorERK-5 inhibitorERK 5 inhibitorERK5 tool molecule inhibitorERK-5 tool molecule inhibitorERK 5 tool molecule inhibitor
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)MAPK7 (ERK5)
Beyond the preview
Go deeper on Ikena Oncology ERK5 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ikena Oncology ERK5 inhibitor.